Literature DB >> 7643912

A kinetic investigation of the pulmonary metabolism of dopamine in rats shows marked differences compared with noradrenaline.

D L Scarcella1, L J Bryan-Lluka.   

Abstract

The aim of this study was to investigate the deamination of dopamine in the intact pulmonary circulation of isolated lungs of the rat. The first part of the study showed that dopamine is not converted to noradrenaline by dopamine-beta-hydroxylase (DBH) when dopamine is perfused through isolated lung preparations with monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) inhibited. Hence, it was not necessary to inhibit DBH in subsequent experiments. The metabolite profile for deamination of dopamine in the lungs was examined by determining whether MAO and semicarbazide-sensitive amine oxidases (SSAO) contribute to the deamination of dopamine (and noradrenaline), and by determining the activity of MAO (kMAO) for the metabolism of dopamine. Lungs were perfused with 1 nmol/l 3H-dopamine or 3H-noradrenaline with COMT inhibited and, in experiments to determine the contribution of SSAO to deamination, with MAO inhibited. Inhibition of MAO reduced the deamination of dopamine and noradrenaline by 99.8% and 98.6%, respectively, indicating that MAO, and not SSAO, was responsible for deamination of the catecholamines in the lungs. The kMAO value for deamination of dopamine was 3.89 min-1. Further experiments were carried out to determine the contributions of MAO-A and MAO-B to the deamination of dopamine in lungs perfused with 1 nmol/l 3H-dopamine and 100 nmol/l lazabemide or 300 nmol/l Ro41-1049, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7643912     DOI: 10.1007/bf00171040

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  38 in total

Review 1.  From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.

Authors:  M Da Prada; R Kettler; H H Keller; A M Cesura; J G Richards; J Saura Marti; D Muggli-Maniglio; P C Wyss; E Kyburz; R Imhof
Journal:  J Neural Transm Suppl       Date:  1990

2.  Uptake and metabolism of catecholamines in the awake dog.

Authors:  F W van Schaik; G M Van Heeswijk; G H Huisman
Journal:  Arch Int Physiol Biochim       Date:  1985-11

3.  Serum dopamine-beta-hydroxylase activity.

Authors:  R Weinshilboum; J Axelrod
Journal:  Circ Res       Date:  1971-03       Impact factor: 17.367

4.  Preferential metabolism of (-) 3 H-norepinephrine through the deaminated glycol in the rat vas deferens.

Authors:  K H Graffe; F J Stefano; S Z Langer
Journal:  Biochem Pharmacol       Date:  1973-05-15       Impact factor: 5.858

5.  The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro.

Authors:  Y S Bakhle; M B Youdim
Journal:  Br J Pharmacol       Date:  1979-01       Impact factor: 8.739

6.  The oxidation of dopamine by the semicarbazide-sensitive amine oxidase (SSAO) from rat vas deferens.

Authors:  J M Lizcano; D Balsa; K F Tipton; M Unzeta
Journal:  Biochem Pharmacol       Date:  1991-04-15       Impact factor: 5.858

7.  Pulmonary extraction of catecholamines in critically ill patients.

Authors:  W J Russell; D B Frewin; J R Jonsson
Journal:  Anaesth Intensive Care       Date:  1982-11       Impact factor: 1.669

Review 8.  Pharmacology and therapeutic use of low-dose dopamine.

Authors:  J F Dasta; M G Kirby
Journal:  Pharmacotherapy       Date:  1986 Nov-Dec       Impact factor: 4.705

9.  Predominance of oxidative deamination in the metabolism of exogenous noradrenaline by the normal and chemically denervated human uterine artery.

Authors:  D Branco; M Caramona; F Martel; J A de Almeida; W Osswald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

10.  Vascular uptake of catecholamines in perfused lungs of the rat occurs by the same process as Uptake1 in noradrenergic neurones.

Authors:  L J Bryan-Lluka; N N Westwood; S R O'Donnell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

View more
  2 in total

Review 1.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

2.  Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats.

Authors:  L J Bryan-Lluka; H Seers; I Sharpe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.